ArticleFrontiers in oncology2026
MRI-derived deep-feature model for differentiating stage I endometrial carcinoma from atypical endometrial hyperplasia: a two-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiating stage I endometrial carcinoma (EC) from atypical endometrial hyperplasia (AEH) before surgery is critical for guiding treatment decisions, yet current magnetic resonance imaging (MRI) assessment is limited by overlapping appearances and inter-observer variability. Methods: In this retrospective, two-center study, 297 patients (153 stage I EC and 144 AEH) who underwent multiparametric MRI were included. Radiomics features were extracted from T2-weighted imaging with fat saturation (T2WI-FS), diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) map, and contrast-enhanced T1-weighted imaging (CE-T1WI) sequences. Feature selections were performed using univariate filtering, correlation analysis, least absolute shrinkage and selection operator (LASSO) and multivariate stepwise regression. A Radiomics model, a Clin+Rad model, and a DenseNet121-derived deep-feature model were constructed and compared for differentiating stage I EC from AEH. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA). Results: Seven radiomics features and eight deep-learning features were ultimately selected to construct the models. In the external validation cohort, the DenseNet121-derived deep-feature model achieved the numerically highest AUC of 0.854 (95% CI, 0.743-0.965), compared with 0.803 (95% CI, 0.673-0.933) for the Radiomics model and 0.773 (95% CI, 0.626-0.919) for the Clin+Rad model, although the pairwise differences in AUC were not statistically significant. In addition, the DenseNet121-derived model showed a relatively greater net clinical benefit at threshold probabilities of approximately 0.15-0.80. SHAP analysis indicated that several influential deep features were derived from ADC images, suggesting that ADC-derived features contributed substantially to the model predictions. Conclusions: The DenseNet121-derived model achieved the numerically highest AUC in the external validation cohort, although the pairwise differences were not statistically significant, indicating its potential as a non-invasive tool to support individualized decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.